Compare Schwab US Large Cap Growth ETF (SCHG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs Smith & Nephew plc — how do they compare? Schwab US Large Cap Growth ETF trades at $35.66, while Smith & Nephew plc trades at $29.59 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while Schwab US Large Cap Growth ETF pays none, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SCHG | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $35.83 | $38.70 |
52-Week Low | $28.10 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG trades at $35.63, down 0.56% today, with a bullish technical outlook driven by strong moving average signals. The ETF's concentrated exposure to AI leaders like Nvidia and Microsoft positions it for growth, though high RSI readings suggest potential near-term consolidation. Recent news highlights institutional activity and the fund's low 0.04% expense ratio as key advantages.
The outlook remains positive given SCHG's alignment with AI infrastructure growth, but risks include heavy tech concentration and sensitivity to interest rates. Wall Street sentiment is mixed, with some analysts citing valuation concerns while others emphasize long-term growth potential.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
